Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVM16 as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors
NCT06541639Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Therapeutic Vaccines, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EVM16 in solid tumor (4 arms), sponsored by Peking University. Primary endpoints: Safety and Tolerability and Recommended Phase 2 Dose up to 1 year. Started Mar 2025; status: recruiting.
02
Drugs
EVM16
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06541639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541639.